source
- AstraZeneca says Wainua failure won’t alter M&A plans, stays on track for $80B 2030 goalAstraZeneca said during its Q2 earnings presentation that the late‑stage failure of the antisense therapy Wainua in ATTR‑cardiomyopathy does not derail its goal of reaching $80 billion in revenue b…
- A trend that isn’t fading, ultra-processed baby foodsAn FDA advisory panel serves some peptide wins, a measles record, and more health news from Morning Rounds